{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:52:30Z","timestamp":1787755950745,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-024-02577-5","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T01:04:42Z","timestamp":1735952682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529)"],"prefix":"10.1186","volume":"20","clinical-trial-number":[{"clinical-trial-number":"umin000022431","registry":"10.18810\/umin-japan"}],"author":[{"given":"Takaaki","family":"Tokito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenobu","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Minato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kageaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifusa","family":"Koreeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuyo","family":"Ogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"issue":"6","key":"2577_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378\u201382. https:\/\/doi.org\/10.1038\/nrclinonc.2011.44.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2577_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8.","journal-title":"J Clin Oncol"},{"issue":"14","key":"2577_CR3","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1002\/cncr.30058","volume":"122","author":"AC Wong","year":"2016","unstructured":"Wong AC, Watson SP, Pitroda SP, et al. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016;122(14):2242\u201350. https:\/\/doi.org\/10.1002\/cncr.30058.","journal-title":"Cancer"},{"key":"2577_CR4","unstructured":"Lussier YA, Xing HR, Salama JK, et al. MicroRNA Expression."},{"issue":"Suppl 4","key":"2577_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):192\u2013237. https:\/\/doi.org\/10.1093\/annonc\/mdy275.","journal-title":"Ann Oncol"},{"issue":"12","key":"2577_CR6","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","volume":"14","author":"AC Dingemans","year":"2019","unstructured":"Dingemans AC, Hendriks LEL, Berghmans T, et al. Definition of synchronous oligo-metastatic non-small cell lung cancer\u2014a consensus report. J Thorac Oncol. 2019;14(12):2109\u201319. https:\/\/doi.org\/10.1016\/j.jtho.2019.07.025.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"2577_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1097\/JTO.0b013e318262caf6","volume":"7","author":"D De Ruysscher","year":"2012","unstructured":"De Ruysscher D, Wanders R, van Baardwijk A, et al. Radical treatment of non\u2013small-cell lung cancer patients with synchronous oligometastases long-term results of a prospective Phase II trial (NCT01282450). J Thorac Oncol. 2012;7(10):1547\u201355. https:\/\/doi.org\/10.1097\/JTO.0b013e318262caf6.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2577_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2013.07.026","volume":"82","author":"A Ashworth","year":"2013","unstructured":"Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82(2):197\u2013203. https:\/\/doi.org\/10.1016\/j.lungcan.2013.07.026.","journal-title":"Lung Cancer"},{"issue":"5","key":"2577_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","volume":"15","author":"AB Ashworth","year":"2014","unstructured":"Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic nonsmall-cell lung cancer. Clin Lung Cancer. 2014;15(5):346\u201355. https:\/\/doi.org\/10.1016\/j.cllc.2014.04.003.","journal-title":"Clin Lung Cancer"},{"key":"2577_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/1471-2407-13-474","volume":"13","author":"SF Su","year":"2013","unstructured":"Su SF, Hu YX, Ouyang WW, et al. Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study. BMC Cancer. 2013;13:474. https:\/\/doi.org\/10.1186\/1471-2407-13-474.","journal-title":"BMC Cancer"},{"issue":"21","key":"2577_CR11","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-na\u00efve patients with advanced-stage non\u2013small-cell lung cancer. J Clin Oncol. 2008;26(21):3543\u201351. https:\/\/doi.org\/10.1200\/JCO.2007.15.0375.","journal-title":"J Clin Oncol"},{"issue":"23","key":"2577_CR12","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","volume":"31","author":"LG Paz-Ares","year":"2013","unstructured":"Paz-Ares LG, de Marinis F, Dediu M, et al. Paramount: final overall survival results of the Phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non\u2013small-cell lung cancer. J Clin Oncol. 2013;31(23):2895\u2013902. https:\/\/doi.org\/10.1200\/JCO.2012.47.1102.","journal-title":"J Clin Oncol"},{"issue":"20","key":"2577_CR13","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1200\/JCO.2009.24.7577","volume":"28","author":"Y Segawa","year":"2010","unstructured":"Segawa Y, Kiura K, Takigawa N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non\u2013small-cell lung cancer: OLCSG 0007. J Clin Oncol. 2010;28(20):3299\u2013306. https:\/\/doi.org\/10.1200\/JCO.2009.24.7577.","journal-title":"J Clin Oncol"},{"issue":"23","key":"2577_CR14","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1200\/JCO.2009.24.5050","volume":"28","author":"N Yamamoto","year":"2010","unstructured":"Yamamoto N, Nakagawa K, Nishimura Y, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable Stage III non\u2013small-cell lung cancer: West Japan thoracic oncology group WJTOG0105. J Clin Oncol. 2010;28(23):3739\u201345. https:\/\/doi.org\/10.1200\/JCO.2009.24.5050.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2577_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/01243894-200610000-00009","volume":"1","author":"I Sekine","year":"2006","unstructured":"Sekine I, Nokihara H, Sumi M, et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable Stage III non-small cell lung cancer. J Thorac Oncol. 2006;1(8):810\u20135.","journal-title":"J Thorac Oncol"},{"issue":"22","key":"2577_CR16","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1801005.","journal-title":"N Engl J Med"},{"issue":"19","key":"2577_CR17","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"issue":"1","key":"2577_CR18","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, et al. Characterization and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organization for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2577_CR19","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol Xin Shelley Wang. 2016;17(12):1672\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(16)30532-0.","journal-title":"Lancet Oncol Xin Shelley Wang"},{"issue":"1","key":"2577_CR20","doi-asserted-by":"publisher","first-page":"173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Zabi W, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer A Phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501.","journal-title":"JAMA Oncol"},{"issue":"11","key":"2577_CR21","doi-asserted-by":"publisher","first-page":"8491","DOI":"10.18632\/oncotarget.3455","volume":"6","author":"DK Reyes","year":"2015","unstructured":"Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6(11):8491\u2013524. https:\/\/doi.org\/10.18632\/oncotarget.3455.","journal-title":"Oncotarget"},{"issue":"20","key":"2577_CR22","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in Stage III non\u2013small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"issue":"9","key":"2577_CR23","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","volume":"5","author":"JM Bauml","year":"2019","unstructured":"Bauml JM, Mick R, Ciunci C, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non\u2013small cell lung cancer A Phase 2 trial. JAMA Oncol. 2019;5(9):1283\u201390.","journal-title":"JAMA Oncol"},{"issue":"11","key":"2577_CR24","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/jamaoncol.2022.4394","volume":"8","author":"R Olson","year":"2022","unstructured":"Olson R, Jiang W, Liu M, et al. Treatment with stereotactic ablative radiotherapy for UP to 5 oligometastases in patients with cancer primary toxic effect results of the nonrandomized Phase 2 SABR-5 clinical trial. JAMA Oncol. 2022;8(11):1644\u201350. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4394.","journal-title":"JAMA Oncol"},{"issue":"10185","key":"2577_CR25","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-comet): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5.","journal-title":"Lancet"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-024-02577-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T13:01:45Z","timestamp":1735995705000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-024-02577-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2577"],"URL":"https:\/\/doi.org\/10.1186\/s13014-024-02577-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4910366\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and Japan\u2019s Clinical Trials Act. The protocol was registered with the University Hospital Medical Information Network, Japan (protocol identification number: UMIN000022431). All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}